VISITECT® CD4 commercialisation update

RNS Number : 9407U

Omega Diagnostics Group PLC

18 July 2018

 

Omega Diagnostics Group PLC

("Omega" or "the Company")

VISITECT® CD4 commercialisation update

Omega (AIM: ODX), the medical diagnostics company focused on allergy, food intolerance and infectious disease, announces the following update on its VISITECT® CD4 commercialisation programme.

The Company announces the appointment of three new dedicated distributors in Ghana, Zambia and Zimbabwe. This follows on from the appointment of their first dedicated distributor for CD4 in Nigeria. All three countries require product registration, which has also commenced. Once completed, this will allow business to business sales to commence through the Company's distributors. The three countries have a high prevalence of people living with HIV and have been priortised on that basis.

Colin King, CEO of Omega commented: "I am pleased to see our commercialisation plan for CD4 taking shape as this is key part of our strategy to delivering shareholder value. This also provides further evidence that our CD4 test (the world's first true point-of-care test) will make a significant difference to people living with HIV in resource-poor environments."

The information communicated in this announcement is inside information for the purposes of Article 7 of EU Regulation 596/2014.

Contacts:

Omega Diagnostics Group PLC	Tel: [phone]
Colin King, Chief Executive	www.omegadiagnostics.com
Kieron Harbinson, Group Finance Director
finnCap Ltd	Tel: [phone]
Geoff Nash/James Thompson (Corporate Finance)
Camille Gochez/ Abigail Wayne (Corporate Broking)
Walbrook PR Limited	Tel: [phone] or [e-mail]
Paul McManus	Mob: [phone]
Lianne Cawthorne	Mob: [phone]

 

END

 

 

UPDEASXXFLFPEFF